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Platelet factor IV and beta-thromboglobulin are protein
constituents of platelet granules. Elevated levelsof these
proteins in plasma have been used as sensitive indicators
of platelet degranulation. Clearance of platelet factor IV
is much faster than that of beta-thromboglobulin after
release of the proteins in vivo. Although increases of
platelet factor IV have been observed in patients with
infarction, the implication that they reflect pathogenetic
phenomena such as coronary thrombosis has not been
assessed explicitly. Accordingly, plasma samples ob-
tained serially from 52 patients with acute myocardial
infarction under rigorous conditions verifiedto minimize
platelet degranulation in vitro were evaluated prospec-
tively. Correlative studies were performed to detect left
ventricular mural thrombus, and coronary thrombosis
was assessed independently in selected patients with in-
dium-Ill platelet scintigraphy.
Platelet factor IV was normal at the time of admission
Release into plasma of platelet factor IV and beta-throm-
boglobulin from platelet granules provides a sensitive index
of platelet degranulation and activation in vivo (1-3). In-
creased platelet factor IV and other manifestations of platelet
aggregation have been reported (4-12) to occur frequently
in association with myocardial infarction. However, the re-
lation of increased platelet factor IV to pathogenetic phe-
nomena such as coronary thrombosis is not clear, nor is its
temporal relation to clinical sequelae associated with myo-
cardial infarction. Platelet factor IV values in plasma sam-
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in patients with infarction, averaging 6.3 ± 3.3 ng/ml,
similar to values in 44 other patients with chest pain
without subsequent infarction (5.7 ± 2.7 nglml) and in
25 normal subjects (4.3 ± 1.6 nglml). Platelet factor IV
generally did not increase during hospitalization in pa-
tients with infarction despite recurrent chest pain, de-
velopment of left ventricular thrombus or documented
recurrent infarction. However, platelet factor IV in-
creased consistently after invasive procedures, account-
ing for 104 of the total of 110 increases due to platelet
activation in vivo as reflected by persistence of elevated
levelsof beta-thromboglobulin. Thus, platelet factor IV
valuesgenerally remain normal despite acute myocardial
infarction. Rare increases that occur reflect platelet de-
granulation in vitro due to sampling artifact or pertur-
bations of platelets in vivo due to invasive procedures.
They do not provide a definitive criterion of coronary
thrombosis.
pIes are prone to spurious elevation due to platelet degran-
ulation in vitro, particularly when conventional sampling
techniques are employed, or could increase in vivo in re-
sponse to invasive procedures . Accordingly, the implication
that increased platelet factor IV in patients with infarction
reflects coronary thrombosi s must be questioned .
The present study was designed to determine the extent
to which increases in platelet factor IV reflect platelet ac-
tivation in vitro as a result of inadequately controlled sam-
pling and processing procedures, or degranulation in vivo
due to invasive procedures. It was performed also to clarify
whether the pattern of serial platelet factor IV values in
patients with infarction can be used to implicate coronary
thrombosis as a pathogenetic mechanism for initial or re-
current injury.
Because measurement s of platelet factor IV in plasma
samples become misleading when degranulation occurs in
vitro , sampling and processing must be controlled rigorously
(13.14). Beta-thromboglobulin released into the circulation
has a half-life of 100 minutes compared with one too short
to be measured for platelet factor IV (3) . Thus, increases
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Figure 2. Elevations of platelet factorIV (PF4)in samples drawn
through a heparin lock. Samples were drawn simultaneously through
a heparin lock in one arm and venipuncture in the other.
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puncture with a 20 gauge needle vacutainer system. Gen-
erally, tourniquets were avoided. Heparin locks were not
utilized because they were found to elicit platelet degran-
ulation in vitro (Fig. 2). Blood was never obtained proximal
to an intravenous line. The initial 3 ml sample was discarded
and the 9.4 ml sample drawn subsequently was collected in
a 10 ml thrombotect tube (Abbott Laboratories) containing
ethlenediaminetetra-acetic acid (EDTA) 2.5%, 2-chlora-
denosine 0.0025% and procaine hydrochloride 7% (weight
per volume).
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Figure 1. Effect of subcutaneous heparin on platelet factor IV
(P.F.4) levels. Subcutaneous heparin (5,000 U) was administered
at the intervals designated by arrows. Increases in platelet factor
IV persisted for as long as 6 hours in some patients.
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Methods
Study patients. Fifty-two patients admitted to the car-
diac care unit at Barnes Hospital with documented acute
myocardial infarction, 44 patients with chest pain without
infarction and 25 normal subjects were studied. All patients
gave informed consent for the protocol, which is part of a
Specialized Center of Research protocol for blood sampling
approved by the Human Experimentation Committee. Cri-
teria for infarction included increased serum creatine kinase
(CK)-MB isoenzyme (> 12 Il.l/liter) and characteristic, se-
rial electrocardiographic changes. In hospitalized patients,
blood samples were obtained for assay of platelet factor IV
and CK-MB beginning at admission and three times daily
until hospital discharge or for 14 days. Beta-thromboglob-
ulin assays were performed in samples with elevated levels
of platelet factor IV and in those collected two sampling
periods before and two after the index sample.
Because subcutaneous heparin is often given to patients
with infarction, a sampling interval was selected to minimize
potential effects of heparin on endothelial release of platelet
factor IV. Heparin (5.000 units subcutaneously) was found
to increase platelet factor IV for as long as 6 hours in three
control studies (Fig. 1). Thus, for patients in this study,
subcutaneous heparin was given on a 12 hourly schedule
and samples for platelet factor IV were obtained at least 6
hours after a dose.
Patients with renal insufficiency (serum creatine kinase
> 2.0 mg/dl), anemia (hematocrit < 37%), thrombocyto-
penia (platelets < 150,000lml), age older than 80 years,
poor venous access or cardiogenic shock were excluded.
Results in patients with infarction (Group I, n = 52) were
compared with those in patients with chest pain without
documented antecedent or subsequent infarction (Group II,
n = 44) and with those in a group of normal volunteers
(Group III, n = 25) including 12 men and 13 women aged
25 to 48 years without known illness. None had received
antiplatelet agents in the past 7 days or smoked a cigarette
within 4 hours of blood drawing.
Assay procedures. Venous blood was obtained by spe-
cially trained technicians using antecubital or forearm veni-
in platelet factor IV attributable to platelet degranulation in
vivo call be differentiated from those due to degranulation
in vitro by concomitantly observed and sustained increases
in beta-thromboglobulin, that is, persistence of elevated lev-
els of beta-thromboglobulin, but a normal level of platelet
factor IV during the next sampling period. Interpretation of
increases in platelet factor IV with reference to assay of
beta-thromboglobulin is also useful because heparin in vivo
does not cause an increase in plasma beta-thromboglobulin
in contrast to platelet factor IV, which increases because of
heparin-induced release of platelet factor IV from vascular
endothelium (2,3).
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Table 1. Platelet Factor IV Values in Patients Without
Infarction (Group II)
Table 2. Clinical Characteristics of Patients With Acute
Myocardial Infarction (Group I)
Day 1 compared with day 2, p = 0,75; day 1 compared with day 3.
p = 047; day 2 compared with day 3. p = 0.53. Data are reported as
mean :±: standard deviation.
Elevated values of platelet factor IV associated with normal
beta-thromboglobulin in the sample obtained after the ob-
served increase were considered to reflect degranulation in
vitro rather than in vivo.
No. of
Patients (%)
27 (52%)
22 (42%)
3 (6%)
16 (31%)
13 (25%)
4 (8%)
30 (58%)
22 (42%)
33 (63%)
19 (37%)
52
60; range 27 to 80
No.
Mean age (yr)
Gender
Male
Female
DIstribution of infarction
Transmural
Nontransmural
Location of infarction
Anterior
Infenor
Lateral
Diabetes
Prior myocardial infarction
Prior coronary artery bypass surgery
No, of Platelet Factor IV
Day Patients (ng/ml)
I 44 5,3 :±: 3,2
2 26 5.6 :±: 2,9
3 6 6,8 :±: 4.0
Results
Absence of infarction. Platelet factor IV values (±
standard deviation) in the 44 patients with chest pain without
infarction (Group II) averaged 5.7 ± 2.7 ng/ml. No values
exceeded 10 ng/ml, Values did not change from day to day
(Table 1). Values in the 25 normal subjects (Group Ill)
averaged 4.3 ± 1.6 ng/rnl. No values exceeded 10 ng/rnl.
Corresponding beta-thromboglobulin values averaged 34.9
± 9.4 ng/ml (n = 23), None exceeded 52 ng/rnl.
Myocardial infarction (Group I). Clinical character-
istics of the patients with infarction are summarized in Table
2. Platelet factor IV values in the samples initially obtained
averaged 6.4 ± 3.3 ng/ml, similar to corresponding values
in samples obtained initially in Groups II and III (5.7 ±
2.7 and 4.3 ± 1.6 ng/rnl, respectively). Platelet factor IV
values did not vary in relation to the interval between the
Alter prompt mixing and transient storage on ice for 30
minutes, samples were centrifuged at 2,500 g in an AIEC
HNS 11 centrifuge for 30 minutes. Any technical problems
encountered during sampling, manifested by slow blood
flow, interrupted flow or hemolysis, were recorded. After
centrifugation, 1 ml of platelet-poor plasma was pipetted
from a region 0.5 em below the meniscus, placed in labeled
polypropylene plastic tubes (platelet factor IV adheres to
glass) and refrigerated at 2 to 4°C before radioimmunoassay
for beta-thromboglobulin and platelet factor IV. Although
plateiet factor IV values (± standard deviation) increased
only by 3,1 ± 3.5 ng/ml (n = 10) in samples stored for 4
days prolonged storage led to marked elevations. Accord-
ingly. all samples were assayed within 4 days. Samples
identified for assay of beta-thromboglobulin were stored at
-70°C and analyzed within I month.
One milliliter of platelet-poor plasma was aspirated into
a separate glass tube containing 20 ILl of mercaptoethanol
and Ilsed for assay of total CK and CK-MB isoenzyme as
descnbed previously (15,16). Values for total CK and CK-
MB collected in the thrombotect solution were indistin-
guishable from those in separate samples drawn in the usual
manner, that is, into media with ethyleneglycol-bis (l3-amino
ethyl ether) N,N'-tetraacetic acid (EGTA) (n = 20 com-
parisons for each). Platelet factor IV was measured by ra-
dioimmunoassay (Abbott Laboratories). Values of 10 ng/ml
or greater were considered elevated. Standards with known
concentrations of platelet factor IV were assayed with each
set ot patient samples to provide criteria for quality control.
Beta-thromboglobulin was assayed conventionally by ra-
dioimmunoassy (Amersham, Inc.). Values of 52 ng/ml or
greater were considered elevated.
Detection of mural thrombus. Two-dimensional echo-
cardiograms (Advanced Technology Laboratories MK 300
C sector scanner with a 3.0 MHz mechanical transducer)
were obtained every 3 days to detect mural thrombus in all
patients with anterior transmural infarction (n = 51 echo-
cardiograms, 13 patients). Apical two and four chamber
projections including views with time-gain compensation
set to provide visualization of structures at shallow depths
were evaluated by three independent observers blinded to
clinical or laboratory data. The presence of thrombi was
determined with the use of Asinger's criteria (17).
Detection of coronary thrombus with indium-
Ill-labeled platelets. In four patients with transmural in-
farcuon, scintigraphy was performed after administration of
indium-Ill-labeled autologous platelets to detect coronary
thrombi. Subtraction of blood pool activity, estimated with
a dual isotope technique, was employed as previously de-
scribed (12).
Analysis of data. Group comparisons of platelet factor
IV and beta-thromboglobulin values were made with the
use of an unpaired Student's t test. Serial values in samples
from the same patient were compared with paired t tests.
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Figure 3. Platelet fact or IV (PF4) and creatine kinase
MB isoenzy me (C K MB) va lues in a patient with un-
complicated inferio r tran smural myocardial infarction.
Platelet fact or IV va lues did not exceed the normal
range ( 10 ng/ml).
onset of symptoms and the time of acquisition of the initial
sample. Samples were obtained within the first 24 hours
after the onset of symptoms in 90% of the patients. Values
in the first sample for patients seen within 6 hours of the
onset of symptoms (n = 14), within the first 12 hours
(n = 24) and within the first 24 hours (n = 9) averaged
5.8 ± 3.4, 6.3 ± 2.9 and 6.4 ± 4.1 ng/ml, respectively.
Platelet factor IV was assayed serially in all patients
with infarction (35.9 :t 6.7 samples per patient) (Fig. 3).
No differences in the pattern or magnitude of values were
seen in patients with transmural compared with nontrans-
mural infarction, in those with anterior compared with in-
ferior infarction, in those with and without prior infarction
or bypass surgery, those with or without diabetes or in those
with or without congestive heart failure (Table 3). The cor-
relation between the mean level of platelet factor IV and
peak CK-MB was poor (r = 0.05). Platelet factor IV values
were not elevated in any sample obtained from the four
Table 3. Relation of Platelet Factor IV to Clinica l Vari ables
Mean
Value of
Platelet
Factor IV
Variable No. (ng/ ml) p Value
Transmural infarction 32 6.7 ± 3. 1 }0.18Nontransmural infarction 20 5.7 ± 1.6
Diabetes 16 5.4 ± 1.7 } 0.10No diabetes 36 6.8 ± 2.9
Anterior myocardia l infarction 27 6.4 ± 2.7 }0.90Infenor myocardial infarction 22 6.5 ± 2.7
Prior myocardial infarction 13 6.3 ::!: 2.1 }0.87No prior myocardial infarction 38 6.4 ::!: 2.8
Prior or concomitant antiplatelet agents 22 6.7 ± 3.7 } 0.37No prior or concomitant antiplatelet agents 30 6.1 ± 1.6
Prior bypass surgery 4 6.4 ± 1.3 } 0.99No prior bypass surgery 48 6.4 ::!: 2.7
Patients with anterior transmural myocardial infarction with mural thrombi 7 68 ::!: 3.0 }
Patients with anterior transmural myocardial infarction without mural thrombi 6 5 I ::!: 1.3 0.14
Values in patients during clinical heart failure (no invasive procedures) 5 6.3 ::!: 1.5 } 0. 15Values in patients without clinical heart failure 30 5.3 ± 1.4
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Table 4. Increases in Platelet Factor IV
No.
Increases associated with hepann therapy 48
In vivo mcreases* 11 0
As-ociated With invasive procedures 104
Others (one patient with presumed thrombotic 6
, oronary occlusion and mural thrombus)
In vit:» mcreascsr 86
Th~ ~
*l ~onfirmed by beta-thromboglobulin; t not confirmed by beta-
thronIhoglobulin.
patients studied scintigraphically with indium-Ill-labeled
platelets despite scintigraphic detection of coronary thrombi
in each.
Elevated levels of platelet fa ctor IV (> 10 ng/ml) were
rare . occurring in only 12% of all samples (244 of a total
of 2 ,028 samples) (Table 4). Seventy-five of the observed
increases were modest (11 to 24 ng/rnl) and 169 more strik-
ing I > 25 ng/ml ). In 48 samples from three patients given
heparin by continuous infusion because of clinical indi-
cations (an example of the effect s of heparin is shown in
Fig. 4). platelet factor IV was elevated but beta-thrornbo-
globulin remained within the normal range. Thus, the ele-
vated levels of platelet factor IV appeared to be due to
heparin-induced release of platelet factor IV from endothe-
lium . Of the 196 increase s in platelet factor IV in patients
who were not treated with heparin, 110 were associated
with persistent increases in beta-thromboglobulin. Such in-
creases were considered to be due to platelet degranulation
in ..ivo. They occurred in 5.4% of a total of 2,028 sample s
obtained . In 86 samples, elevations of both platelet factor
IV .md beta-thromboglobulin had returned to normal by the
next sample. These sample s met criteria for degranulation
in vitro and appeared randomly distributed throughout the
study group. The vast majority (66%) were greater than 25
ng/rnl.
Technical difficulties in sampling were prospectively
identified in 56% (48 instances) of the 86 samples that met
criteria for degranulation in vitro by beta-thromboglobulin .
Sampling problems were identified in an additional 103
samples without increa ses in platelet factor IV. In 83%,
slow or interrupted blood flow occurred; in 8%, multiple
venipunctures were required and in 9% a hemolyzed sample
was noted after centrifugation despite a clean venipuncture
and smooth uninterrupted flow.
Invasive procedures (Table 5). Seventeen patient s
underwent 19 invasive procedures (insertion of a Swan-
Ganz catheter or a transvenous pacemaker electrode). Among
the 15 patients with baseline platelet factor IV results avail-
able . platelet factor IV values increased in 14 after the
procedure by an average of 8.6 ± 8.6 ng/m!. Among the
14 patients in whom baseline beta-thromboglobulin values
were available , these values increased in 13 (Fig . 5) . Ele-
vated levels of platelet factor IV in association with invasive
procedures represented 104 of the total of 110 increa ses
attributable to platelet degranulation in vivo . They generally
persisted until removal of the catheter or pacemaker elec-
trode. Subsequentl y, platelet factor IV promptly returned to
baseline while beta-thromboglobulin decreased more slowly
in keeping with its longer biologic half-life .
Recurrent chest pain (Fig. 6). Recurrent chest pain in
the absence of recurrent infarction occurred in 34 of the 52
patients (97 episodes) . Platelet factor IV did not increase
before or after such episodes .
Left ventricular thrombus. Th irteen patients with an-
terior transmural infarction were evaluated with serial two-
dimensional echocardiography . A left ventricular thrombu s
was documented in seven . In six, neither platelet factor IV
values in initial samples (6.8 ± 3.0 ng/ml) nor subsequent
values increased before or after formation of the thrombus
detectable by echocardiography (Fig. 4) . Thus, the pattern
and magnitude of levels of platelet factor IV were identical
among patients with and without ventricular thrombus . The
Figure 4. Platelet factor IV (PF4) and creatine kinase
MB isoenzyme (CK MB) values in a patient with an-
terior myocardial infarction who developed an apical
thrombus. Heparin was given at the time designated
by the arrow , resulting in increases in platelet factor
IV. Beta-thromboglobulin remained normal; it also re-
mamed normal in the sample on day 2 after platelet
factor IV had increased modestly in a sample compro-
mised by technical difficulties.
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before
procedure
Mean value
during
procedure
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Platelet Factor IV
(ng/ml)
8.2:±: 4'7}
P < 0.001
16.8 ± 9.9
Beta-
Thromboglobulin
(ng/rnl)
48 ± 267}
P = 0.034
125 ± 155
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seventh patient with mural thrombus manifested markedly
elevated platelet factor IV levels and persistently elevated
levels of beta-thromboglobulin. She was a 27 year old woman
who had used oral contraceptive agents before sustaining
an anterior myocardial infarction. Coronary arteriography 2
weeks after the episode delineated a recanalized left anterior
descending coronary artery, but no coronary atherosclerosis.
Recurrent infarction (Fig. 6). Eight patients had early
recurrent infarction (10 recurrences) reflected by reelevation
of CK-MB, three patients with initial transmural and five
patients with initial nontransmural infarction. Platelet factor
IV did not increase before or after any of these episodes.
Discussion
Results of this study indicate that platelet factor IV gen-
erally does not increase in association with acute myocardial
infarction. Elevated levels did not presage complications
Figure 5. Platelet factor IV (PF4) and beta-thromboglobulin (BTG)
after invasive procedures. In 14 of 15 samples, values increased
after the procedure by a mean of 8.5 ± 8.6 ng/m!. The dashed
line indicates the upper limit of norma!.
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Figure 6. Values of platelet factor IV (PF4) in a patient with
nontransmural myocardial infarction, chest pain and subsequent
early recurrent infarction. Increases in platelet factor IV did not
occur before, during or after episodes of chest pain (arrows) or
in association with recurrent injury on days 9 and 10 (when creatine
kinase MB [CK MB] became elevated).
potentially attributable to thrombosis and associated platelet
aggregation, such as recurrent chest pain, mural thrombus
or recurrent infarction. Those increases attributable to plate-
let degranulation in vivo were modest and generally oc-
curred after invasive procedures. Because such increases
were accompanied by increases in beta-thromboglobulin, it
is unlikely that they were due to heparin used in conjunction
with the procedures. Although patients who require Swan-
Ganz catheterization or pacemaker placement are, as a rule,
in less stable condition than others, increases occurred only
after the invasive procedures, suggesting they were related
to the procedure itself rather than to more severe infarction.
Comparison with previous data. Our results are sim-
ilar to those of Pumphrey and Dawes (18), who evaluated
serial levels of beta-thromboglobulin in patients with acute
myocardial infarction, and those of other investigators (13,
14), who emphasized the need for meticulous sampling pro-
cedures. Platelet factor IV values were not affected by treat-
ment with antiplatelet agents (aspirin, dipyridamole or sul-
finpyrazone), an observation consistent with results of recent
pharmacologic studies (19). Many reports (4-8) of elevated
levels of platelet factor IV in association with infarction
have been based on analysis of isolated or infrequently drawn
samples. Differences in components used in the anticoag-
ulant/antiaggregant media may have accounted for increases
in platelet factor IV in some studies. Such differences could
affect samples from patients with acute infarction compared
with normal subjects differentially if their platelets were
more sensitive to conditions in vitro of suboptimal antico-
agulation or antiaggregation. These factors have been ex-
tensively reviewed by others (20).
Present study. To clarify apparent disparities among
results of previous studies and to assess the potential utility
of platelet factor IV as a criterion of coronary thrombosis,
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we designed the present study according to several consid-
erations including early initiation of sampling, serial sam-
pling, differentiation of platelet degranulation in vitro and
in vivo, prospective recording of unavoidable sampling dif-
ficulties potentially affecting platelet factor IV values,
avoidance of misinterpretation due to heparin-induced re-
least of platelet factor IV from endothelium and avoidance
of artifact induced by inadequately rigorous sampling or
processing procedures,
After invasive procedures, beta-thromboglobulin re-
mained elevated, whereas platelet factor IV returned promptly
to a normal value, supporting the use of persistent increases
in beta-thromboglobulin to confirm degranulation in vitro,
Many of these increases were detected by careful monitoring
of the sampling procedure; however, the sensitivity and
specificity of careful monitoring alone would not have iden-
tified samples with and without degranulation in vitro. If
beta ·thromboglobulin had not been measured, 86 increases
in platelet factor IV attributed to platelet degranulation in
vitro might have been attributed spuriously to platelet de-
graulation in vivo, Even if our criteria utilizing beta-throm-
boglobulin erroneously excluded a few true increases in
platelet factor IV, no pattern to these additional values could
be detected.
Clinical implications. Our findings indicate that ele-
vation of platelet factor IV is not a common antecedent or
concomitant condition of acute myocardial infarction. The
few increases in platelet factor IV that are encountered are
most often associated with invasive procedures or platelet
degranulation in vitro, Thus, elucidation of coronary throm-
bOSIS and the contributions of platelet aggregation to pre-
cipitation of myocardial infarction or its complications will
prohably require assessment of regional platelet deposition
(121 or the development of more sensitive systemic indexes
of platelet activation in vivo,
We appreciate the assistance of Roseanne Wettach, RN, MNP, Keith A
A. F,)~, MB, ChB, Irwin Weinstein, MD, Paul R. Eisenberg, MD, Cynthia
Ritter and Kenneth Schechtman, PhD.
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